CA2393452A1 - Utilisation de l'histamine comme compose ameliorant la liberation de medicaments dans l'administration par voie transmuqueuse ou transdermique - Google Patents

Utilisation de l'histamine comme compose ameliorant la liberation de medicaments dans l'administration par voie transmuqueuse ou transdermique Download PDF

Info

Publication number
CA2393452A1
CA2393452A1 CA002393452A CA2393452A CA2393452A1 CA 2393452 A1 CA2393452 A1 CA 2393452A1 CA 002393452 A CA002393452 A CA 002393452A CA 2393452 A CA2393452 A CA 2393452A CA 2393452 A1 CA2393452 A1 CA 2393452A1
Authority
CA
Canada
Prior art keywords
histamine
composition
transmucosally
enhancing agent
transmucosal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002393452A
Other languages
English (en)
Inventor
Judy Senior
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Maxim Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2393452A1 publication Critical patent/CA2393452A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition à administration transmuqueuse à pénétration améliorée comprenant: entre environ 0,001 % et environ 25 % d'un agent améliorant la perméation choisi dans le groupe composé de l'histamine, du dichlorhydrate d'histamine, du phosphate d'histamine, d'un sel pharmaceutiquement acceptable de ces derniers, d'autres agonistes de l'histamine; entre environ 0,2 % et environ 90 % d'un médicament pharmaceutiquement actif; entre environ 0 % et environ 99,8 % d'un solvant; et entre environ 0 % et environ 50 % d'un agent gélifiant.
CA002393452A 1999-07-30 2000-07-28 Utilisation de l'histamine comme compose ameliorant la liberation de medicaments dans l'administration par voie transmuqueuse ou transdermique Abandoned CA2393452A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14664199P 1999-07-30 1999-07-30
US60/146,641 1999-07-30
PCT/US2000/020757 WO2001008706A1 (fr) 1999-07-30 2000-07-28 Utilisation de l'histamine comme compose ameliorant la liberation de medicaments dans l'administration par voie transmuqueuse ou transdermique

Publications (1)

Publication Number Publication Date
CA2393452A1 true CA2393452A1 (fr) 2001-02-08

Family

ID=22518302

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002393452A Abandoned CA2393452A1 (fr) 1999-07-30 2000-07-28 Utilisation de l'histamine comme compose ameliorant la liberation de medicaments dans l'administration par voie transmuqueuse ou transdermique

Country Status (5)

Country Link
EP (1) EP1229939A1 (fr)
AU (1) AU6751000A (fr)
CA (1) CA2393452A1 (fr)
HK (1) HK1048770A1 (fr)
WO (1) WO2001008706A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089661A1 (fr) * 2013-12-17 2015-06-25 Contech Enterprises Inc. Composés, compositions et procédés pour attirer et/ou retenir des punaises des lits

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016068336A1 (fr) * 2014-10-30 2016-05-06 旭化成ケミカルズ株式会社 Agent et agent auxiliaire de promotion d'absorption transdermique
CN110075063A (zh) * 2019-05-27 2019-08-02 合肥亿帆生物医药有限公司 一种二盐酸组胺注射液及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4521405A (en) * 1982-05-17 1985-06-04 John McMichael Methods and materials for treatment of disease states involving immunological factors
HU223205B1 (hu) * 1996-12-03 2004-03-29 Zoltán Dárdai Helyileg alkalmazható készítmény peptidszerű gyógyhatású vegyületek élő szervezetbe vitelére
US6270781B1 (en) * 1999-01-08 2001-08-07 Maxim Pharmaceuticals, Inc. Method and compositions for topical treatment of damaged tissue using reactive oxygen metabolite production or release inhibitors

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015089661A1 (fr) * 2013-12-17 2015-06-25 Contech Enterprises Inc. Composés, compositions et procédés pour attirer et/ou retenir des punaises des lits
CN105899074A (zh) * 2013-12-17 2016-08-24 西蒙弗雷泽大学 用于吸引和/或捕捉臭虫的化合物、组合物和方法
AU2014366768B2 (en) * 2013-12-17 2017-10-12 Simon Fraser University Compounds, compositions and methods for attracting and/or arresting bed bugs
RU2678226C1 (ru) * 2013-12-17 2019-01-24 Саймон Фрейзер Юниверсити Соединения, композиции и способы приманивания и/или поимки постельных клопов
CN105899074B (zh) * 2013-12-17 2019-09-24 西蒙弗雷泽大学 用于吸引和/或捕捉臭虫的化合物、组合物和方法
US11553717B2 (en) 2013-12-17 2023-01-17 Simon Fraser University Compounds, compositions and methods for attracting and/or arresting bed bugs

Also Published As

Publication number Publication date
AU6751000A (en) 2001-02-19
WO2001008706A1 (fr) 2001-02-08
EP1229939A1 (fr) 2002-08-14
HK1048770A1 (zh) 2003-04-17

Similar Documents

Publication Publication Date Title
US20030143195A1 (en) Use of histamine as a drug delivery enhancing compound for use in transmucosal or transdermal delivery
JP3786684B2 (ja) オキシブチニンの経皮投与
US6319510B1 (en) Gum pad for delivery of medication to mucosal tissues
JP2671248B2 (ja) 薬効または化粧効果成分の浸透性増進方法
JP2547726B2 (ja) フェンタニルの皮膚投与およびそのための装置
CA1329132C (fr) Methode d'administration du deprenyl, permettant de reduire au minimum les effets secondaires du produit
US5120545A (en) Reduction or prevention of sensitization to drugs
KR100861443B1 (ko) 경비투여용 방출 조절 전달 시스템
JP4338313B2 (ja) 粉末状経鼻組成物
US20100034880A1 (en) Pharmaceutical compositions based on a microemulsion
US20020068080A1 (en) Administering pharmaceuticals to the mammalian central nervous system
JPH11158081A (ja) 薬剤供給システム
WO1994010987A1 (fr) Procedes d'administration d'analgesiques combines pour le traitement de la douleur
KR910014117A (ko) 하이드로알콜성 겔을 사용한 이부프로펜의 경피전달 방법
JP2004500360A (ja) 皮膚浸透促進剤としての水酸化物放出剤
JPH09505279A (ja) オキシブチニンのためのモノグリセリド／乳酸エステル透過促進剤
WO1993008798A1 (fr) Timbre et composition a base de pentamidine
TW200418487A (en) Pharmaceutical composition for topical delivery of meloxicam comprising an amine or amine as penetration enhancer.
CA2079106A1 (fr) Systemes de delivrance des medicaments contenant un extrait fluide d'eriodictyon comme excipient, et methodes et compositions qui y sont associees
US5149539A (en) Reduction or prevention of sensitization to drugs
CA2393452A1 (fr) Utilisation de l'histamine comme compose ameliorant la liberation de medicaments dans l'administration par voie transmuqueuse ou transdermique
WO1993023019A1 (fr) Dispositifs d'apport medicamenteux transcutane, compositions qui y sont associees et procedes d'utilisation
ES2201176T3 (es) Administracion transdermica con velocidad de difusion controlada de risperidona.
HRP20000400A2 (en) Transmucosal formulations of levosimendal
JP2002535293A (ja) 無針の経皮的粉末薬物送達を増強する方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead